Nutritional modulation of parathyroid hormone secretion may influence risk for left ventricular hypertrophy

Medical Hypotheses

Volumn 64, Issue 5, 2005, Pages 1015-1021

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CALCIFEDIOL; CALCIUM; ENDOSTATIN; NORADRENALIN; PARATHYROID HORMONE; PROTEIN KINASE C; PROTEIN KINASE C BETA; RENIN; VITAMIN D;

ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE MONITORING; CALCIUM INTAKE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; EXERCISE; GENE OVEREXPRESSION; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; HYPERPARATHYROIDISM; LIFESTYLE; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; RADIATION EXPOSURE; RENIN RELEASE; TRANSGENIC MOUSE; ULTRAVIOLET RADIATION; VITAMIN SUPPLEMENTATION;

EID: 15244358531     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.054     Document Type: Article

References (95)

1. Shane E., Mancini D., Aaronson K., Silverberg S.J., Seibel M.J., Addesso V., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am. J. Med. 103:1997;197-207
2. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J. Am. Coll. Cardiol. 41:2003;105-112
3. Nishio K., Mukae S., Aoki S., Itoh S., Konno N., Ozawa K., et al. Congestive heart failure is associated with the rate of bone loss. J. Intern. Med. 253:2003;439-446
4. Christ E., Linka A., Junga G., Odermatt M., Steinert H., Kiowski W., et al. Bone density and laboratory parameters of bone metabolism in patients with terminal heart disease. Schweiz. Med. Wochenschr. 126:1996;1553-1559
5. Schmid C., Kiowski W. Hyperparathyroidism in congestive heart failure. Am. J. Med. 104:1998;508-509
6. Kelm M., Schafer S., Mingers S., Heydthausen M., Vogt M., Motz W., et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J. Hypertens. 14:1996;1357-1364
7. White M. Cardioprotective effect of angiotensin II receptor antagonists. Can. J. Cardiol. 15(Suppl F):1999;10F-14F
8. Ehmke H., Faulhaber J., Munter K., Kirchengast M., Wiesner R.J. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension. 33:1999;954-960
9. Hua L., Li C., Xia D., Qu P., Li Z., Zhang W., et al. Relationship between hypertensive left ventricular hypertrophy and levels of endothelin and nitric oxide. Hypertens. Res. 23:2000;377-380
10. Wolf S.C., Gaschler F., Brehm S., Klaussner M., Amann K., Risler T., et al. Endothelin-receptor antagonists in uremic cardiomyopathy. J. Cardiovasc. Pharmacol. 36:2000;S348-S350
11. Knowlton K.U., Michel M.C., Itani M., Shubeita H.E., Ishihara K., Brown J.H., et al. The α1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:1993;15374-15380
12. Long C.S., Kariya K., Karns L., Simpson P.C. Sympathetic activity: modulator of myocardial hypertrophy. J. Cardiovasc. Pharmacol. 17(Suppl 2):1991;S20-S24
13. Sadoshima J., Xu Y., Slayter H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:1993;977-984
14. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265:1990;20555-20562
15. 2+-sensitive isoforms in the failing human heart. Circulation. 99:1999;384-391
16. Simpson P.C. β-Protein kinase C and hypertrophic signaling in human heart failure. Circulation. 99:1999;334-337
17. Kariya K., Karns L.R., Simpson P.C. An enhancer core element mediates stimulation of kinase C in hypertrophy of the rat β-myosin heavy chain promoter by an α1-adrenergic agonist and activated β-protein cardiac myocytes. J. Biol. Chem. 269:1994;3775-3782
18. Karns L.R., Kariya K., Simpson P.C. M-CAT, CArG, and Sp1 elements are required for α1-adrenergic induction of the skeletal α-actin promoter during cardiac myocyte hypertrophy. Transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. J. Biol. Chem. 270:1995;410-417
19. Wakasaki H., Koya D., Schoen F.J., Jirousek M.R., Ways D.K., Hoit B.D., et al. Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. USA. 94:1997;9320-9325
20. MacLellan W.R., Schneider M.D. Success in failure: modeling cardiac decompensation in transgenic mice. Circulation. 97:1998;1433-1435
21. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA. 94:1997;8121-8126
22. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., et al. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. USA. 95:1998;10140-10145
23. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F.J., Neer E.J. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. USA. 95:1998;13893-13898
24. Feuerstein G.Z., Rozanski D. G proteins and heart failure: is Gαq a novel target for heart failure? Circ. Res. 87:2000;1085-1086
25. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 280:1998;574-577
26. Wettschureck N., Rutten H., Zywietz A., Gehring D., Wilkie T.M., Chen J., et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nat. Med. 7:2001;1236-1240
27. Takeishi Y., Chu G., Kirkpatrick D.M., Li Z., Wakasaki H., Kranias E.G., et al. In vivo phosphorylation of cardiac troponin I by protein kinase C β2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J. Clin. Invest. 102:1998;72-78
28. Schluter K.D., Piper H.M. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am. J. Physiol. 263:1992;H1739-H1746
29. Schluter K.D., Weber M., Piper H.M. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem. J. 310(Pt 2):1995;439-444
30. Schluter K.D., Piper H.M. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc. Res. 37:1998;34-41
31. McGonigle R.J., Fowler M.B., Timmis A.B., Weston M.J., Parsons V. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron. 36:1984;94-100
32. London G.M., de Vernejoul M.C., Fabiani F., Marchais S.J., Guerin A.P., Metivier F., et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int. 32:1987;900-907
33. Meggs L.G. The cardiocyte as a target for parathyroid hormone in end-stage renal disease. J. Assoc. Acad. Minor. Phys. 5:1994;59-61
34. Hara S., Ubara Y., Arizono K., Ikeguchi H., Katori H., Yamada A., et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner. Electrolyte Metab. 21:1995;72-76
35. Park C.W., Oh Y.S., Shin Y.S., Kim C.M., Kim Y.S., Kim S.Y., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33:1999;73-81
36. Strozecki P., Adamowicz A., Nartowicz E., Odrowaz-Sypniewska G., Wlodarczyk Z., Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren. Fail. 23:2001;115-126
37. Symons C., Fortune F., Greenbaum R.A., Dandona P. Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism - an association. Brit. Heart J. 54:1985;539-542
38. Dominiczak A.F., Lyall F., Morton J.J., Dargie H.J., Boyle I.T., Tune T.T., et al. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. Clin. Sci. (Lond.). 78:1990;127-132
39. Sato S., Ohta M., Kawaguchi Y., Okada H., Ono M., Saito H., et al. Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner. Electrolyte Metab. 21:1995;67-71
40. Stefenelli T., Abela C., Frank H., Koller-Strametz J., Niederle B. Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery. 121:1997;157-161
41. Piovesan A., Molineri N., Casasso F., Emmolo I., Ugliengo G., Cesario F., et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin. Endocrinol. (Oxf.). 50:1999;321-328
42. Bauwens F.R., Duprez D.A., De Buyzere M.L., De Backer T.L., Kaufman J.M., Van Hoecke J., et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol. 68:1991;925-929
43. Hui Y., Hao Y., Chen X., Jing S., Dai Z. Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension. Chin. Med. J. (Engl.). 109:1996;885-887
44. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110:2002;229-238
45. Sigmund C.D. Regulation of renin expression and blood pressure by vitamin D(3). J. Clin. Invest. 110:2002;155-156
46. Petrov V., Lijnen P. Modification of intracellular calcium and plasma renin by dietary calcium in men. Am. J. Hypertens. 12:1999;1217-1224
47. McCarty MF. Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses 2004 [in press]
48. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69:1999;842-856
49. Vieth R., Chan P.C., MacFarlane G.D. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 73:2001;288-294
50. Portale A.A., Halloran B.P., Morris R.C.J. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J. Clin. Invest. 83:1989;1494-1499
51. Zhang M.Y., Wang X., Wang J.T., Compagnone N.A., Mellon S.H., Olson J.L., et al. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin d-1α-hydroxylase gene expression in the proximal renal tubule. Endocrinology. 143:2002;587-595
52. Rodriguez M., Almaden Y., Hernandez A., Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr. Opin. Nephrol. Hypertens. 5:1996;321-328
53. Barsotti G., Morelli E., Cupisti A., Meola M., Dani L., Giovannetti S. A low-nitrogen low-phosphorus Vegan diet for patients with chronic renal failure. Nephron. 74:1996;390-394
54. Soroka N., Silverberg D.S., Greemland M., Birk Y., Blum M., Peer G., et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron. 79:1998;173-180
55. Kempson S.A., Lotscher M., Kaissling B., Biber J., Murer H., Levi M. Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules. Am. J. Physiol. 268:1995;F784-F791
56. Holick M.F. Vitamin D: a millenium perspective. J. Cell. Biochem. 88:2003;296-307
57. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Brit. J. Nutr. 89:2003;552-572
58. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl. J. Med. 322:1990;1561-1566
59. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114:1991;345-352
60. Ghali J.K., Liao Y., Simmons B., Castaner A., Cao G., Cooper R.S. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med. 117:1992;831-836
61. Schmieder R.E., Schlaich M.P. Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv. Exp. Med. Biol. 432:1997;191-198
62. Sharp A., Mayet J. Regression of left ventricular hypertrophy: hoping for a longer life. J. Renin. Angiotensin. Aldosterone. Syst. 3:2002;141-144
63. Beil A.H., Schmieder R.E., Messerli F.H. Salt intake, blood pressure, and cardiovascular structure. Cardiovasc. Drugs. Ther. 8:1994;425-432
64. Schmieder R.E., Langenfeld M.R., Friedrich A., Schobel H.P., Gatzka C.D., Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 94:1996;1304-1309
65. Heimann J.C., Drumond S., Alves A.T., Barbato A.J., Dichtchekenian V., Marcondes M. Left ventricular hypertrophy is more marked in salt-sensitive than in salt-resistant hypertensive patients. J. Cardiovasc. Pharmacol. 17(Suppl 2):1991;S122-S124
66. Jula A.M., Karanko H.M. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation. 89:1994;1023-1031
67. Denton D., Weisinger R., Mundy N.I., Wickings E.J., Dixson A., Moisson P., et al. The effect of increased salt intake on blood pressure of chimpanzees. Nat. Med. 1:1995;1009-1016. [see comments]
68. MacGregor G.A., de Wardener H.E. Salt, diet and health: Neptune's poisoned chalice: the origins of high blood pressure. 1998;Cambridge University Press, Cambridge
69. de Wardener H.E., MacGregor G.A. Sodium and blood pressure. Curr. Opin. Cardiol. 17:2002;360-367
70. Militante J.D., Lombardini J.B. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids. 23:2002;381-393
71. Fujita T., Ando K., Noda H., Ito Y., Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 75:1987;525-532
72. Sato Y., Ogata E., Fujita T. Hypotensive action of taurine in DOCA-salt rats - involvement of sympathoadrenal inhibition and endogenous opiate. Jpn. Circ. J. 55:1991;500-508
73. Azuma J., Sawamura A., Awata N., Ohta H., Hamaguchi T., Harada H., et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin. Cardiol. 8:1985;276-282
74. Azuma J. Long-term effect of taurine in congestive heart failure: preliminary report. Heart Failure Research with Taurine Group. Adv. Exp. Med. Biol. 359:1994;425-433
75. Digiesi V., Cantini F., Oradei A., Bisi G., Guarino G.C., Brocchi A., et al. Coenzyme Q10 in essential hypertension. Mol. Aspects Med. 15(Suppl 1):1994;s257-s263
76. Burke B.E., Neuenschwander R., Olson R.D. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South. Med. J. 94:2001;1112-1117
77. Baggio E., Gandini R., Plancher A.C., Passeri M., Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol. Aspects Med. 15(Suppl 1):1994;s287-s294
78. Soja A.M., Mortensen S.A. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol. Aspects Med. 18(Suppl 1):1997;S159-S168
79. Sasson Z., Rasooly Y., Bhesania T., Rasooly I. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation. 88:1993;1431-1436
80. Lind L., Andersson P.E., Andren B., Hanni A., Lithell H.O. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J. Hypertens. 13:1995;433-438
81. Kamide K., Nagano M., Nakano N., Yo Y., Kobayashi R., Rakugi H., et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am. J. Hypertens. 9:1996;1165-1171
82. Watanabe K., Sekiya M., Tsuruoka T., Funada J., Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J. Hypertens. 17:1999;1153-1160
83. Facchini F.S., Stoohs R.A., Reaven G.M. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am. J. Hypertens. 9:1996;1013-1017
84. Watanabe K., Sekiya M., Tsuruoka T., Funada J., Kameoka H., Miyagawa M., et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J. Hypertens. 17:1999;1161-1168
85. Barnard R.J., Ugianskis E.J., Martin D.A., Inkeles S.B. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am. J. Cardiol. 69:1992;440-444
86. Turner M.J., Spina R.J., Kohrt W.M., Ehsani A.A. Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. J. Gerontol. A: Biol. Sci. Med. Sci. 55:2000;M245-M251
87. Hulter H.N., Melby J.C., Peterson J.C., Cooke C.R. Chronic continuous PTH infusion results in hypertension in normal subjects. J. Clin. Hypertens. 2:1986;360-370
88. Fliser D., Franek E., Fode P., Stefanski A., Schmitt C.P., Lyons M., et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol. Dial. Transplant. 12:1997;933-938
89. Lind L., Wengle B., Wide L., Sorensen O.H., Ljunghall S. Hypertension in primary hyperparathyroidism - reduction of blood pressure by long-term treatment with vitamin D (αcalcidol). A double-blind, placebo-controlled study. Am. J. Hypertens. 1:1988;397-402
90. Raine A.E., Bedford L., Simpson A.W., Ashley C.C., Brown R., Woodhead J.S., et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int. 43:1993;700-705
91. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 30:1997;150-156
92. Rostand S.G. Seasonal changes in blood pressure in patients undergoing hemodialysis. New Engl. J. Med. 340:1999;965-966
93. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet. 352:1998;709-710
94. Sacks F.M., Rosner B., Kass E.H. Blood pressure in vegetarians. Am. J. Epidemiol. 100:1974;390-398
95. Beilin L.J., Rouse I.L., Armstrong B.K., Margetts B.M., Vandongen R. Vegetarian diet and blood pressure levels: incidental or causal association? Am. J. Clin. Nutr. 48:1988;806-810